{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:44:21Z","timestamp":1791225861774,"version":"4.1.0"},"reference-count":104,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite expanded access to antiretroviral therapy (ART) and the rollout of the World Health Organization's (WHO) \u2018test\u2010and\u2010treat\u2019 strategy, the proportion of people with HIV (PWH) presenting with advanced HIV disease (AHD) remains unchanged at approximately 30%. Fifty percent of persons with AHD report prior engagement to care. ART failure and insufficient retention in HIV care are major causes of AHD. People living with AHD are at high risk for opportunistic infections and death. In 2017, the WHO published guidelines for the management of AHD that included a comprehensive package of care for screening and prophylaxis of major opportunistic infections (OIs). In the interim, ART regimens have evolved: integrase inhibitors are first\u2010line therapy globally, and the diagnostic landscape is evolving. The objective of this review is to highlight novel point\u2010of\u2010care (POC) diagnostics and treatment strategies that can facilitate OI screening and prophylaxis for persons with AHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the WHO guidelines for recommendations for persons with AHD. We summarized the scientific literature on current and emerging diagnostics, along with emerging treatment strategies for persons with AHD. We also highlight the key research and implementation gaps together with potential solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While POC CD4 testing is being rolled out in order to identify persons with AHD, this alone is insufficient; implementation of the Visitect CD4 platform has been challenging given operational and test interpretation issues. Numerous non\u2010sputum POC TB diagnostics are being evaluated, many with limited sensitivity. Though imperfect, these tests are designed to provide rapid results (within hours) and are relatively affordable for resource\u2010poor settings. While novel POC diagnostics are being developed for cryptococcal infection, histoplasmosis and talaromycosis, implementation science studies are urgently needed to understand the clinical benefit of these tests in the routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite progress with HIV treatment and prevention, a persistent 20%\u201330% of PWH present to care with AHD. Unfortunately, these persons with AHD continue to carry the burden of HIV\u2010related morbidity and mortality. Investment in the development of additional POC or near\u2010bedside CD4 platforms is urgently needed. Implementation of POC diagnostics theoretically could improve HIV retention in care and thereby reduce mortality by overcoming delays in laboratory testing and providing patients and healthcare workers with timely same\u2010day results. However, in real\u2010world scenarios, people with AHD have multiple comorbidities and imperfect follow\u2010up. Pragmatic clinical trials are needed to understand whether these POC diagnostics can facilitate timely diagnosis and treatment, thereby improving clinical outcomes such as HIV retention in care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.13487","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T22:51:08Z","timestamp":1681253468000},"page":"859-876","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Advanced\n                    <scp>HIV<\/scp>\n                    disease: A review of diagnostic and prophylactic strategies"],"prefix":"10.1111","volume":"24","author":[{"given":"Alice","family":"Lehman","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and International Medicine University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Ellis","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Nalintya","sequence":"additional","affiliation":[{"name":"Infectious Disease Institute Makerere University  Kampala Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Bahr","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases University of Kansas  Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Loyse","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity Research Institute St George's University of London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Rajasingham","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Medicine University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Joint United Nations Programme on HIV and AIDS (UNAIDS). Fast\u2010track commitments to end AIDS by 2030.2020. Accessed March 22 2021.https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/fast-track-commitments_en.pdf"},{"key":"e_1_2_8_3_1","unstructured":"Joint United Nations Programme on HIV and AIDS (UNAIDS).AIDSinfo.2020Accessed March 22 2021.https:\/\/aidsinfo.unaids.org\/"},{"key":"e_1_2_8_4_1","unstructured":"World Health Organization.Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy (p.56).2017Accessed March 22 2021.https:\/\/www.who.int\/publications\/i\/item\/9789241550062."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy045"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad087"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25401"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002627"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615822"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60164-7"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00329-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00295-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25775"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003006"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31267-4"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.19.1.20714"},{"key":"e_1_2_8_17_1","unstructured":"United States President's Emergency Plan For AIDS Relief (PEPFAR)PEPFAR 2019 Country Operational Plan Guidance for all PEPFAR Countries.2019Accessed March 22 2021.https:\/\/www.state.gov\/wp-content\/uploads\/2019\/08\/PEPFAR-Fiscal-Year-2019-Country-Operational-Plan-Guidance.pdf."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25546"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy122"},{"key":"e_1_2_8_20_1","unstructured":"SikombeK Eshun\u2010WilsonI KoyuncuA et al.Early mortality in HIV\u2010infected patients initiating ART without a pretherapy CD4. Conference on Retroviruses and Opportunistic Infections. March 4\u201372019Seattle Washington."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318235b378"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230453"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003092"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2020.v110i2.13823"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-3948-x"},{"key":"e_1_2_8_26_1","volume-title":"Global tuberculosis report 2022","author":"World Health Organization (WHO)","year":"2022"},{"key":"e_1_2_8_27_1","volume-title":"Global tuberculosis report 2021","author":"World Health Organization (WHO)","year":"2021"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000802"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1402"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02128-9"},{"key":"e_1_2_8_31_1","unstructured":"BraniganD.Pipeline Report: Tuberculosis Diagnostics.2021.https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2021\/11\/pipeline_TB_diagnostics_2021_final.pdf"},{"key":"e_1_2_8_32_1","unstructured":"World Health Organization (WHO).WHO guidelines on tuberculosis infection prevention and control: 2019 update.2019Accessed March 22 2021.https:\/\/www.who.int\/publications\/i\/item\/9789241550512"},{"key":"e_1_2_8_33_1","unstructured":"World Health Organization (WHO).WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection.2021Accessed June 27 2022.https:\/\/www.who.int\/publications\/i\/item\/9789240029415"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa100"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00062-3"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01847-18"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S284157"},{"key":"e_1_2_8_38_1","unstructured":"Foundation for Innovative New Diagnostics (FIND).World Health Organization endorses Truenat tests for initial diagnosis of tuberculosis and detection of rifampicin resistance. Accessed June 27 2022.https:\/\/www.finddx.org\/publications\u2010and\u2010statements\/world\u2010health\u2010organization\u2010endorses\u2010truenat\u2010tests\u2010for\u2010initial\u2010diagnosis\u2010of\u2010tuberculosis\u2010and\u2010detection\u2010of\u2010rifampicin\u2010resistance\/"},{"key":"e_1_2_8_39_1","volume-title":"WHO consolidated guidelines on tuberculosis: module 3: diagnosis \u2010rapid diagnostics for tuberculosis detection","author":"World Health Organization (WHO)","year":"2021"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0156"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","unstructured":"ByashaliraKMP SemvuaH ChilongolaJ et al.Clinical outcomes of new algorithm for diagnosis and treatment of tuberculosis sepsis in HIV patients.2019Accessed June 27 2022.https:\/\/www.ijmyco.org\/article.asp?issn=2212\u20105531;year=2019;volume=8;issue=4;spage=313;epage=319;aulast=Byashalira#ref16","DOI":"10.4103\/ijmy.ijmy_135_19"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.08.005"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00087-8"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00074-21"},{"key":"e_1_2_8_45_1","volume-title":"Xpert MTB\u2010XDR English Package Insert","author":"Cepheid","year":"2021"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab839"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2009679"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"e_1_2_8_49_1","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID).Drug\u2010drug interactions between rifapentine and dolutegravir in HIV\/LTBI co\u2010infected individuals.2020Accessed September 2 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04272242"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00499-6"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1086\/655143"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01238-18"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1243"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00441-20"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.11.017"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001669"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001894"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix872"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-020-00431-2"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2811.220542"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30354-2"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6030165"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009286"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562899"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.87271"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof5030076"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009215"},{"key":"e_1_2_8_68_1","unstructured":"DiagnosticsMV.Histoplasma Urine Antigen LFA Test Kit.2021."},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof7100799"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab454"},{"key":"e_1_2_8_71_1","unstructured":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV\u2010infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention the National Institutes of Health and the HIV Medicine Association of the Infectious Diseases Society of America.2016Accessed April 8 2021.https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult\u2010and\u2010adolescent\u2010opportunistic\u2010infection\/cryptococcosis"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1086\/514744"},{"key":"e_1_2_8_73_1","volume-title":"Diagnosing and Managing Disseminated Histoplasmosis Among People Living with HIV","author":"Pan American Health Organization and World Health Organization","year":"2020"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-012-9577-0"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12530"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-464"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa826"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1588078"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70917-X"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2010.02528.x"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.05.018"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit596"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70072-4"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262938"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02257-15"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy472"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0349-6"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-019-0675-4"},{"key":"e_1_2_8_89_1","volume-title":"Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022\u20132032","author":"World Health Organization (WHO)","year":"2022"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.13.1533"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.10.030"},{"key":"e_1_2_8_92_1","volume-title":"Single dose liposomal amphotericin for asymptomatic cryptococcal antigenemia","author":"Meya DB NE","year":"2019"},{"key":"e_1_2_8_93_1","unstructured":"Govender N MS.Treatment of cryptococcal antigen\u2010positive patients identified through screening using fluconazole plus flucytosine vs. fluconazole alone.2021. Accessed September 2 2022.https:\/\/www.isrctn.com\/ISRCTN30579828"},{"key":"e_1_2_8_94_1","volume-title":"Lateral flow urine lipoarabinomannan assay (LF\u2010LAM) for the diagnosis of active tuberculosis in people living with HIV: an updated systematic review","author":"Bjerrum SSI","year":"2019"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140461"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03999-2020"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1698"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.5588\/pha.20.0062"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218890"},{"issue":"1","key":"e_1_2_8_100_1","first-page":"Cd000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","volume":"2010","author":"Akolo C","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000985"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1835"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1019"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0609"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T20:58:31Z","timestamp":1692305911000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":104,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/hiv.13487"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13487","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"2023-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}